Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta, Roberto Borea, Andreia Coelho, et al.
Critical Reviews in Oncology/Hematology (2017) Vol. 113, pp. 256-267
Open Access | Times Cited: 189

Showing 1-25 of 189 citing articles:

FGF/FGFR signaling in health and disease
Yangli Xie, Nan Su, Jing Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 600
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Toshimitsu Yamaoka, Sojiro Kusumoto, Koichi Andō, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3491-3491
Open Access | Times Cited: 245
<p>Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies</p>
Fiona H. Tan, Tracy L. Putoczki, Stanley S. Stylli, et al.
OncoTargets and Therapy (2019) Vol. Volume 12, pp. 635-645
Open Access | Times Cited: 164
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito, et al.
Cancer Research (2020) Vol. 80, Iss. 22, pp. 4986-4997
Open Access | Times Cited: 156
Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Guihong Liu, Tao Chen, Zhenyu Ding, et al.
Cell Proliferation (2021) Vol. 54, Iss. 4
Open Access | Times Cited: 133
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges
Claudia Maria Ascione, Fabiana Napolitano, Daniela Esposito, et al.
Cancer Treatment Reviews (2023) Vol. 115, pp. 102530-102530
Closed Access | Times Cited: 109
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
Valentina Tateo, Paola Valeria Marchese, Veronica Mollica, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 614-614
Open Access | Times Cited: 48
Targeting FGFR for cancer therapy
Pei Zhang, Lin Yue, Qingqing Leng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment
Federica Laudisi, Fabio Cherubini, Giovanni Monteleone, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 6, pp. 1787-1787
Open Access | Times Cited: 115
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
Sareshma Sudhesh Dev, Syafiq Asnawi Zainal Abidin, Reyhaneh Farghadani, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 96
Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
Brendan Farrell, Alexander L. Breeze
Biochemical Society Transactions (2018) Vol. 46, Iss. 6, pp. 1753-1770
Open Access | Times Cited: 93
Future applications of FGF/FGFR inhibitors in cancer
Gaia C. Ghedini, Roberto Ronca, Marco Presta, et al.
Expert Review of Anticancer Therapy (2018) Vol. 18, Iss. 9, pp. 861-872
Closed Access | Times Cited: 89
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
Chiara Casadei, Nazlı Dizman, Giuseppe Schepisi, et al.
Therapeutic Advances in Medical Oncology (2019) Vol. 11
Open Access | Times Cited: 88
Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules
Zhangxu He, Yunpeng Gong, Xin Zhang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112946-112946
Closed Access | Times Cited: 84
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Shalini Makawita, Ghassan K. Abou‐Alfa, Sameek Roychowdhury, et al.
Future Oncology (2020) Vol. 16, Iss. 30, pp. 2375-2384
Closed Access | Times Cited: 83
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies
Liwei Lang, Yong Teng
Cells (2019) Vol. 8, Iss. 1, pp. 31-31
Open Access | Times Cited: 80
Expedition of sulfur‐containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: A decade update
Kritika Laxmikeshav, Kumari Pooja, Nagula Shankaraiah
Medicinal Research Reviews (2021) Vol. 42, Iss. 1, pp. 513-575
Closed Access | Times Cited: 75
Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Zhichao Tian, Xiaohui Niu, Weitao Yao
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 71
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
Jakub Szymczyk, Katarzyna Dominika Sluzalska, Izabela Materla, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5796-5796
Open Access | Times Cited: 61
Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review
Jia Zheng, Wei Zhang, Linfeng Li, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 52
Fibroblast growth factor signaling in macrophage polarization: impact on health and diseases
Luyao Shen, Yongsheng Li, Huakan Zhao
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
A Comprehensive Review of Current Approaches in Bladder Cancer Treatment
Soniya Kumbham, Kazi Md Mahabubur Rahman, Barbara A. Foster, et al.
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 2, pp. 286-307
Closed Access | Times Cited: 1
Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer Treatment
Natalia Porębska, Marta Latko, Marika Kucińska, et al.
Journal of Clinical Medicine (2018) Vol. 8, Iss. 1, pp. 7-7
Open Access | Times Cited: 82
Natural products as important tyrosine kinase inhibitors
Bo Yin, Dongmei Fang, Xian‐Li Zhou, et al.
European Journal of Medicinal Chemistry (2019) Vol. 182, pp. 111664-111664
Closed Access | Times Cited: 76
TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw
Carolina Cavaliéri Gomes, Tenzin Gayden, Andrea Bajic, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 72
Page 1 - Next Page

Scroll to top